Acura Pharmaceuticals Inc (ACUR) Annual Income Statement ()
ACUR Quarterly Financials ()
Frequently Asked Questions About Acura Pharmaceuticals Inc (ACUR) Stock
Acura Pharmaceuticals Inc's (ACUR) last reported annual revenue was USD 1.56 Million.
Acura Pharmaceuticals Inc's (ACUR) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A
Acura Pharmaceuticals Inc's(ACUR) is not profitable as of its last reported annual financials.
The net profit margin for Acura Pharmaceuticals Inc's(ACUR) from its laster reported year is -56.24%
The return on equity (ROE) for Acura Pharmaceuticals Inc's(ACUR) from its last reported annual financials is : 0.00%
The return on assets (ROA) for Acura Pharmaceuticals Inc's(ACUR) from its last reported annual financials is : -58.46%
The return on invested capital (ROIC) for Acura Pharmaceuticals Inc's(ACUR) from its last reported annual financials is : -343.91%
The Debt to Equity ratio for Acura Pharmaceuticals Inc's(ACUR) from its last reported annual financials is : 84.27%
The dividend yield for Acura Pharmaceuticals Inc's(ACUR) from its laster reported year is 0.00%
Acura Pharmaceuticals Inc's(ACUR) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ACUR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
